Business Context and Reporting Period
This Form 8-K is a current report filed by BioSig Technologies, Inc. (not Streamex Corp.) on April 23, 2020. The registrant is a Delaware corporation with its principal executive offices in Westport, Connecticut. The report covers events occurring on April 23 and April 24, 2020, primarily concerning the company's subsidiary, ViralClear Pharmaceuticals, Inc., and its product candidate, merimepodib.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and clinical development milestones rather than financial performance data.
Material Changes and Events
- Annual Meeting Rescheduling: The Board established June 26, 2020, as the date for the 2020 Annual Meeting of Stockholders, with a record date of April 28, 2020. This change exceeds 30 days from the 2019 anniversary date.
- Shareholder Proposal Deadline: Due to the meeting date change, the deadline for stockholder proposals or nominations under Rule 14a-8 is set for May 4, 2020, at 5:00 p.m. Eastern Time.
- Clinical Data Publication: On April 23, 2020, ViralClear published comparative in vitro data on merimepodib and remdesivir activity against COVID-19 in F1000 Research.
- Regulatory Submission: On April 24, 2020, ViralClear submitted an Investigational New Drug (IND) Application to the FDA for a Phase II clinical trial of merimepodib as a treatment for COVID-19.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or management commentary on future financial performance. The primary outlook relates to the clinical development of merimepodib for COVID-19. The company announced a conference call to discuss recent developments. No specific risks or contingencies are detailed in the text of this 8-K, though the success of the Phase II trial is implied as a critical future event.
Investor Verification Checklist
- Verify the details of the in vitro data comparing merimepodib and remdesivir published in F1000 Research (Exhibit 99.1).
- Confirm the status of the FDA's review of the Investigational New Drug (IND) Application for the Phase II trial (Exhibit 99.2).
- Review the company's amended and restated bylaws regarding the specific requirements for stockholder proposals and nominations.
- Check for the transcript or recording of the conference call announced for April 24, 2020 (Exhibit 99.3).